---
title: "Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule | SCLX Stock News"
description: "Scilex Holding Company has regained compliance with NASDAQ's minimum bid price requirement, maintaining a closing bid price of $1.00 per share for ten consecutive trading days as of April 30, 2025. Th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/238349020.md"
published_at: "2025-04-30T17:46:00.000Z"
---

# Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule | SCLX Stock News

> Scilex Holding Company has regained compliance with NASDAQ's minimum bid price requirement, maintaining a closing bid price of $1.00 per share for ten consecutive trading days as of April 30, 2025. The company's common stock and public warrants will continue to trade on the Nasdaq Capital Market under the symbols "SCLX" and "SCLXW". Scilex focuses on non-opioid pain management products and has several FDA-approved treatments and product candidates in its portfolio.

04/30/2025 - 01:46 PM

PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least ten consecutive trading days. This requirement was met on April 30, 2025.

The Company’s common stock and public warrants will continue to trade on the Nasdaq Capital Market under the symbols “SCLX” and “SCLXW”, respectively.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

**About Scilex Holding Company**

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex Holding Company is headquartered in Palo Alto, California.

**Forward-Looking Statements**

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease.

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex’s ability to remain in compliance with the Nasdaq continued listing requirements and to maintain the listing of the Company’s securities thereon; Scilex’s ability to develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

**Contacts:**

Investors and Media  
Scilex Holding Company  
960 San Antonio Road  
Palo Alto, CA 94303  
Office: (650) 516-4310  
Email: investorrelations@scilexholding.com  
Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

### Related Stocks

- [SCLX.US - Scilex](https://longbridge.com/en/quote/SCLX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Scilex Holding Co Closes First Tranche of $50M Loan Agreement | On December 22, 2025, Scilex Holding Co closed the first tranche of a $50 million loan agreement. Key Highlights: First  | [Link](https://longbridge.com/en/news/270532879.md) |
| Scilex Completes $27 Million Repurchase of Oramed Penny Warrants | Scilex Holding Company has completed a $27 million repurchase of 6,500,000 "Penny Warrants" from Oramed Pharmaceuticals  | [Link](https://longbridge.com/en/news/271139113.md) |
| Datavault AI (NASDAQ:DVLT) Major Shareholder Sells $3,683,221.92 in Stock | Datavault AI Inc. (NASDAQ:DVLT) major shareholder Holding Co Scilex sold 5,115,586 shares at an average price of $0.72,  | [Link](https://longbridge.com/en/news/272630912.md) |
| Scilex Holding Secures Up to $50 Million Loan from St. James Bank & Trust | Scilex Holding Company has secured a Non-Recourse Loan and Securities Pledge Agreement with The St. James Bank & Trust C | [Link](https://longbridge.com/en/news/268801277.md) |
| Scilex Holding Company Issues Unregistered Warrant in Private Placement | Scilex Holding Company completed a private placement, raising $20.3 million through warrant exercises. Investors receive | [Link](https://longbridge.com/en/news/267402978.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
